These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23606826)

  • 1. Dual PPAR α / γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia.
    Samuelsson O; Attman PO; Gause-Nilsson I; Svensson MK; Alaupovic P
    PPAR Res; 2013; 2013():391628. PubMed ID: 23606826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects.
    Hughes TA; Stentz F; Gettys T; Smith SR
    Metabolism; 2006 Jan; 55(1):26-34. PubMed ID: 16324916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance.
    Schuster H; Fagerberg B; Edwards S; Halmos T; Lopatynski J; Stender S; Birketvedt GS; Tonstad S; Gause-Nilsson I; Halldórsdóttir S; Ohman KP;
    Atherosclerosis; 2008 Mar; 197(1):355-62. PubMed ID: 17631296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans.
    Shah A; Rader DJ; Millar JS
    Atherosclerosis; 2010 May; 210(1):35-40. PubMed ID: 20005515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
    Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
    Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
    Goldstein BJ; Rosenstock J; Anzalone D; Tou C; Ohman KP
    Curr Med Res Opin; 2006 Dec; 22(12):2575-90. PubMed ID: 17166340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease.
    Samuelsson O; Attman PO; Knight-Gibson C; Kron B; Larsson R; Mulec H; Weiss L; Alaupovic P
    Nephron; 1997; 75(3):286-94. PubMed ID: 9069450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The compositional abnormalities of lipoproteins in diabetic renal failure.
    Attman PO; Knight-Gibson C; Tavella M; Samuelsson O; Alaupovic P
    Nephrol Dial Transplant; 1998 Nov; 13(11):2833-41. PubMed ID: 9829487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.
    Ooi EM; Chan DT; Watts GF; Chan DC; Ng TW; Dogra GK; Irish AB; Barrett PH
    J Lipid Res; 2011 Apr; 52(4):794-800. PubMed ID: 21297177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor.
    Bisgaier CL; Essenburg AD; Barnett BC; Auerbach BJ; Haubenwallner S; Leff T; White AD; Creger P; Pape ME; Rea TJ; Newton RS
    J Lipid Res; 1998 Jan; 39(1):17-30. PubMed ID: 9469582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of decreasing renal function on lipoprotein profiles.
    Attman PO; Samuelsson O; Alaupovic P
    Nephrol Dial Transplant; 2011 Aug; 26(8):2572-5. PubMed ID: 21220758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.
    Attman PO; Alaupovic P; Tavella M; Knight-Gibson C
    Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women.
    Wassef H; Bissonnette S; Dufour R; Davignon J; Faraj M
    J Nutr; 2017 May; 147(5):754-762. PubMed ID: 28356429
    [No Abstract]   [Full Text] [Related]  

  • 15. Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III.
    Chan DT; Dogra GK; Irish AB; Ooi EM; Barrett PH; Chan DC; Watts GF
    J Lipid Res; 2009 Dec; 50(12):2524-31. PubMed ID: 19542564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.
    Chan DC; Watts GF; Redgrave TG; Mori TA; Barrett PH
    Metabolism; 2002 Aug; 51(8):1041-6. PubMed ID: 12145779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein abnormalities without hyperlipidaemia in moderate renal insufficiency.
    Samuelsson O; Attman PO; Knight-Gibson C; Kron B; Larsson R; Mulec H; Weiss L; Alaupovic P
    Nephrol Dial Transplant; 1994; 9(11):1580-5. PubMed ID: 7870346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.
    Chan DC; Nguyen MN; Watts GF; Barrett PH
    J Clin Endocrinol Metab; 2008 Feb; 93(2):557-64. PubMed ID: 18000086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.